Indoleamine 2,3-Dioxygenase-Expressing Aortic Plasmacytoid Dendritic Cells Protect against Atherosclerosis by Induction of Regulatory T Cells.
Indoleamine 2,3-Dioxygenase-Expressing Aortic Plasmacytoid Dendritic Cells Protect against Atherosclerosis by Induction of Regulatory T Cells.
复制标题
表达吲哚胺 2,3-双加氧酶的主动脉浆细胞样树突状细胞通过诱导调节性 T 细胞预防动脉粥样硬化
DOI：
10.1016/j.cmet.2016.04.010
复制
发表时间：
2016
期刊：
影响因子：
29
通讯作者：
Cheong C
中科院分区：
文献类型：
--
作者：
Yun TJ;Lee JS;Machmach K;Shim D;Jang HS;Jung I-H;Choi J;Yoon WK;Miah MA;Bego MG;Pham TNQ;Loschko J;Krug AB;Lee S-P;Keler T;Guimond JV;Haddad E;Cohen EA;Sirois MG;El-Hamamsy I;Colonna M;Choi J-H;Cheong C
自身免疫性疾病（AIDS）是一组异质性免疫介导的疾病，是一个主要的和日益严重的健康问题。虽然目前艾滋病主要用抗炎和免疫抑制药物治疗，但干细胞移植在艾滋病患者中的应用正变得越来越普遍。然而，干细胞移植治疗具有局限性，包括可用干细胞的短缺和来自非自体来源的细胞的免疫排斥。诱导多能干细胞（iPSC）技术，允许产生患者特异性多能干细胞，可以为艾滋病患者的干细胞治疗的临床应用提供替代来源。我们使用非整合的oriP/EBNA-1为基础的附加型载体重编程皮肤成纤维细胞从艾滋病患者，如强直性脊柱炎（AS），干燥综合征（SS）和系统性红斑狼疮（SLE）。验证了每个患者特异性iPSC系的多能性和多谱系分化能力。这些iPSC用于干细胞移植的安全性由所有AIDS特异性iPSC是整合的无转基因的事实指示。最后，本研究中衍生的所有艾滋病特异性iPSC可以在体外分化为造血和间充质谱系的细胞，如通过流式细胞术分析和诱导终末分化潜能所示。我们的结果表明，从AS、SS和SLE患者中成功产生了无整合的iPSC。这些发现支持了将iPSC技术用于各种艾滋病（包括AS、SS和SLE）的自体和同种异体细胞替代疗法的可能性。
Autoimmune diseases (AIDs), a heterogeneous group of immune-mediated disorders, are a major and growing health problem. Although AIDs are currently treated primarily with anti-inflammatory and immunosuppressive drugs, the use of stem cell transplantation in patients with AIDs is becoming increasingly common. However, stem cell transplantation therapy has limitations, including a shortage of available stem cells and immune rejection of cells from nonautologous sources. Induced pluripotent stem cell (iPSC) technology, which allows the generation of patient-specific pluripotent stem cells, could offer an alternative source for clinical applications of stem cell therapies in AID patients. We used nonintegrating oriP/EBNA-1-based episomal vectors to reprogram dermal fibroblasts from patients with AIDs such as ankylosing spondylitis (AS), Sjögren’s syndrome (SS) and systemic lupus erythematosus (SLE). The pluripotency and multilineage differentiation capacity of each patient-specific iPSC line was validated. The safety of these iPSCs for use in stem cell transplantation is indicated by the fact that all AID-specific iPSCs are integrated transgene free. Finally, all AID-specific iPSCs derived in this study could be differentiated into cells of hematopoietic and mesenchymal lineages in vitro as shown by flow cytometric analysis and induction of terminal differentiation potential. Our results demonstrate the successful generation of integration-free iPSCs from patients with AS, SS and SLE. These findings support the possibility of using iPSC technology in autologous and allogeneic cell replacement therapy for various AIDs, including AS, SS and SLE.
登录
查看更多内容
影响因子：
32.4
作者：
Swiecki M;Gilfillan S;Vermi W;Wang Y;Colonna M
通讯作者：
Colonna M
影响因子：
32.4
作者：
Hadeiba H;Lahl K;Edalati A;Oderup C;Habtezion A;Pachynski R;Nguyen L;Ghodsi A;Adler S;Butcher EC
通讯作者：
Butcher EC
DOI：
10.1073/pnas.0710351105
发表时间：
2008-02-26
影响因子：
11.1
作者：
Watarai, Hiroshi;Sekine, Etsuko;Taniguchi, Masaru
通讯作者：
Taniguchi, Masaru
影响因子：
37.8
作者：
Doering, Yvonne;Manthey, Helga D.;Zernecke, Alma
通讯作者：
Zernecke, Alma
影响因子：
32.4
作者：
Jakubzick C;Gautier EL;Gibbings SL;Sojka DK;Schlitzer A;Johnson TE;Ivanov S;Duan Q;Bala S;Condon T;van Rooijen N;Grainger JR;Belkaid Y;Ma'ayan A;Riches DW;Yokoyama WM;Ginhoux F;Henson PM;Randolph GJ
通讯作者：
Randolph GJ